| P/E (FY) | 23.8 | Sales (TTM) | $9.94B |
| Earnings (TTM) | $1.37B | ROE | — |
| Net Margin | 13.07% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | −25.04% | Sales Growth 3Y | −0.94% |
Biogen is a global biopharmaceutical company focused on neurology, specialized immunology, and rare diseases. Its marketed products include multiple sclerosis treatments (VUMERITY, TYSABRI, TECFIDERA, AVONEX, PLEGRIDY), SPINRAZA for spinal muscular atrophy, SKYCLARYS for Friedreich's ataxia, QALSODY for ALS, and biosimilars BENEPALI, IMRALDI, and FLIXABI. The company also collaborates with Eisai on LEQEMBI for Alzheimer's disease and with Genentech on multiple anti-CD20 therapies. Biogen supports its pipeline through internal R&D, external collaborations, and acquisitions. In 2025 it acquired Alcyone Therapeutics, a clinical-stage company developing an implantable intrathecal delivery platform for CNS therapies, including SPINRAZA. Products are commercialized in the U.S., E.U., and international markets.
| Market Cap | $30.89B | Trading Days | 6679 |
| 52W High | 219.72 |
| 52W Low | 124.56 |
| % Off High | −4.77% |
| YTD | 18.89% | 1Y | 63.59% |
| 3Y | −22.56% | 5Y | −36.44% |
| 10Y | −27.83% | Since incept. (ann.) | 7.44% |
Reportable 100%
| Ann. Volatility (1Y) | 35.71% | Ann. Volatility (3Y) | 30.36% |
| Sharpe (1Y) | 1.54 | Sharpe (3Y) | −0.11 |
| Max Drawdown (1Y) | −14.34% | Max Drawdown (3Y) | −58.64% |
| Beta (3Y, vs SPY) | 0.34 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| RVMD | Revolution Medicines, Inc. | $38.46B | — |
| MRNA | Moderna, Inc. | $21.62B | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | $18.18B | 38.7 |
| EXEL | EXELIXIS, INC. | $13.91B | 19.9 |
| TECH | BIO-TECHNE Corp | $11.28B | 156.6 |
| KRYS | Krystal Biotech, Inc. | $10.71B | 53.1 |
| HALO | HALOZYME THERAPEUTICS, INC. | $9.88B | 32.5 |
| QGEN | QIAGEN N.V. | $9.07B | — |
| KYMR | Kymera Therapeutics, Inc. | $8.66B | — |
| APGE | Apogee Therapeutics, Inc. | $8.14B | — |
| RGEN | REPLIGEN CORP | $7.97B | 164.2 |
| IMVT | Immunovant, Inc. |
| $7.93B |
| — |